NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
Status:
Recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
Anaplastic thyroid cancer (ATC) is an almost invariable lethal cancer in humans.
Most patients present with a rapid progressive mass in the neck with progressive complaints
like dyspnoea, dysphagia or pain. The risk of suffocation is the main reason for rapid
surgical intervention, but we know from literature that an oncological resection with clear
margins is seldomly achieved. Some patients deteriorate that fast after surgery that
radiation therapy and/or chemotherapy is not feasible anymore. Patients with BRAF-mutated ATC
already have shown to benefit from targeted BRAF/MEK inhibition. This study aims to increase
the number of patients that undergo a successful R0 tumor resection after neo-adjuvant
BRAF/MEK inhibitor treatment.